{
    "organizations": [],
    "uuid": "57964de6d9bc76a075b0d7e3968d77affa2417d5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-luye-pharma-groups-drug-approved-b/brief-luye-pharma-groups-drug-approved-by-u-s-fda-idUSFWN1PY0MJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Luye Pharma Group's Drug Approved By U.S. FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Luye Pharma Group Ltd:\n* ‍GROUP‘S DRUG ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS BEEN APPROVED BY U.S. FDA\n* DRUG IS EXEMPTED FROM PHASE II DOSAGE EXPLORATION CLINICAL TRIALS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T16:42:00.000+02:00",
    "crawled": "2018-02-09T17:09:27.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "luye",
        "pharma",
        "group",
        "ltd",
        "drug",
        "rotigotine",
        "extended",
        "release",
        "microspheres",
        "injection",
        "approved",
        "fda",
        "drug",
        "exempted",
        "phase",
        "ii",
        "dosage",
        "exploration",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}